The FDA has shown its' hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options. […]

The mRNA Process Development & CMC Summit returns for its 5th Anniversary, bringing together the brightest minds in mRNA development, manufacturing, and CMC strategy. As the field continues to evolve at pace, this milestone edition is your opportunity to connect, learn, and stay ahead of the curve with the leaders shaping the future of mRNA […]

10th Anniversary Edition of the IPF Summit - September 29 – October 1, 2026 | Boston, MA For a decade, the IPF Summit has been the go-to, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year, the stakes, and the opportunity, have never been higher. Following a wave of positive […]

AI is no longer a future concept in life sciences – it is actively reshaping how work gets done, how decisions are made, and how value is created. Yet most organisations are still navigating how to move from ambition to enterprise-wide execution. The Designing the AI-Enabled Life Sciences Workforce Summit Europe is the only forum built […]

Fueled by surging digital pathology partnerships, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs, the precision medicine field is evolving rapidly. Building on this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns to Boston this fall, uniting 850+ senior stakeholders in the common goal of advancing timely, accessible and […]

Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes. With 7 streams of end-to-end ADC content across Discovery […]

Early Access Programmes have evolved into a critical, but increasingly complex, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines, evidence generation, and patient access across global markets. The 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning […]

4th Covalent Drug Discovery & Development Summit (October 20–22, Boston, MA) Covalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns, advances in chemistry, screening technologies, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology. As the field evolves, the challenge is no […]

Cell and gene therapies are advancing into late-stage development and commercialization, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny, inflating cost of goods, and causing delays that put timelines and patient access at risk. Following the sunshine to […]

After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15B worth of upfront […]

The 14th IMPACCT Real-World Evidence Summit is the only dedicated industry forum uniting leaders across RWE, real-world data, evidence generation, HEOR, and market access to tackle the most pressing challenges in the field. From selecting regulatory-ready datasets to embedding AI and advanced analytics into workflows, this summit focuses on how to consistently translate data into […]

GLP-1s changed the treatment paradigm for obesity reaching new heights of efficacy. Now, as unmet need persists and the field looks beyond efficacy alone, momentum is building behind therapies that can deliver lasting weight management through improved tolerability, muscle preservation, personalised treatment approaches, and more convenient administration. As obesity investment and pipeline activity surge across […]